Financial Highlights and Market Update slide image

Financial Highlights and Market Update

USA, Europe, Canada and Australia (Core Markets) ☐ Revenue: We delivered a strong performance with growth in existing products including Micafungin, Enoxaparin, Heparin, Dexmedetomidine among and among others new prod- uct launches. It was also an important milestone to launch our first set of penem products for the US market. ■ New launches(2); Q1 FY21: 17 Product SKUS (12 molecules) US filings update: As of June 30, 2021, we along with our partners had 286 ANDA filings in the United States, of which 239 were approved and 47 pending approval. ANDA Filed ANDA Approved DMFS Filed Q1 FY22 2 6(3) LO 6% USA Q1 FY22: Rs. 7,042 Mn YoY Growth: 16% Core Markets (1) Revenue Contribution Q1 FY21 63% 7% Q1 FY22 54% 7 Note: ANDA count includes technology transfer ANDAS Europe, Canada and Australia (1) Core markets includes USA, Europe, Canada and Australia (2) Includes products where launch quantity is dispatched to our partners (3) Received final approval for one product which was earlier tentatively approved GLAND
View entire presentation